Page 1

Metagenomi THERAPEUTICS Exhibit 99.1 Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results Remains on track to submit investigational new drug ( IND ) application in 4Q 2026 for the global clinical program of MGX - 001 for the treatment of hemophilia A $ 120.7 million in cash , cash equivalents , and available - for - sale marketable securities as of June 30 , 2026 , with runway anticipated to support operations through 4Q 2027 EMERYVILLE , Calif . , August 10 , 2026 ( GLOBE NEWSWIRE ) Metagenomi Therapeutics , Inc. ( Nasdaq : MGX ) ( the “ Company ” ) , an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients , today reported financial results for the second quarter ended June 30 , 2026 , and provided business updates . " During the second quarter , we continued to execute against our strategic priorities while advancing toward our planned regulatory submissions for our MGX - 001 program in hemophilia A later this year , " said Jian Irish , Ph.D. , M.B.A. , President and Chief Executive Officer of Metagenomi Therapeutics . " As we prepare to enter the clinic , we are engaging with leading hemophilia investigators and key opinion leaders to establish a strong foundation for our first - in - human study . We believe our differentiated genome editing platform positions us to pursue durable genetic medicines , and we remain focused on disciplined execution as we move toward our upcoming regulatory and clinical milestones . " Second Quarter 2026 Updates MGX - 001 - Hemophilia A Program • • IND - enabling studies for MGX - 001 are expected to be complete by the end of the third quarter of 2026 , including GLP toxicity . The Company remains on track to submit an IND application in the fourth quarter of 2026 for the global clinical program , and subject to regulatory clearance , initiate clinical trials in 2027 . Two Metagenomi scientific posters received Top Poster Awards at the 2026 International Society on Thrombosis and Haemostasias ( ISTH ) Congress in Paris , Frace , including one highlighting extensive non - human primate preclinical data supporting MGX - 001 . MGX - 001 - Large Gene Integration System for Protein Replacement via Gene Insertion • The Company continues to evaluate disease indications which have the potential to be treated by protein replacement via gene insertion . Second Quarter 2026 Financial Results